Science history: A tragic gene therapy death that stalled the field for a decade — Sept. 17, 1999
By Tia Ghose
Copyright livescience
Skip to main content
Close main menu
Live Science
Sign up to our newsletter
View Profile
Search Live Science
Planet Earth
Archaeology
Physics & Math
Human Behavior
Science news
Life’s Little Mysteries
Science quizzes
Newsletters
Story archive
Pawnee Star Chart
JWST ‘starlit mountaintop’ photo
Ant clones members of another species
COVID vaccine poll
Best star projecter
Don’t miss these
Medicine & Drugs
8-year-old with rare, fatal disease shows dramatic improvement on experimental treatment
Medicine & Drugs
Experimental treatment for high cholesterol edits DNA in the body to reduce LDL
8 babies spared from potentially deadly inherited diseases through new IVF ‘mitochondrial donation’ trial
Medicine & Drugs
Breakthrough cystic fibrosis drug that extends life by decades earns its developers a $250,000 ‘American Nobel’
Scraps of ancient viruses make up 40% of our genome. They could trigger brain degeneration.
Diabetic man produces his own insulin after gene-edited cell transplant
Medicine & Drugs
Unpacking RFK Jr.’s (many) false claims about COVID vaccines
Fungus that may have caused ‘King Tut’s curse’ shows promise in treating cancer
Medicine & Drugs
‘These decisions were completely reckless’: Funding cuts to mRNA vaccines will make America more vulnerable to pandemics
Diet change could make brain cancer easier to treat, early study hints
Chemotherapy can make healthy blood cells ‘look old’
Gain-of-function research is not the ‘purview of mad scientists.’ It’s fundamental to biology.
Best-ever map of the human genome reveals ‘hidden’ regions of DNA
‘Universal’ cancer vaccine heading to human trials could be useful for ‘all forms of cancer’
The rare genetic disease that gives babies hard ‘scales’
Science history: A tragic gene therapy death that stalled the field for a decade — Sept. 17, 1999
17 September 2025
Sept. 17, 1999: Jesse Gelsinger died after receiving a gene therapy treatment to treat a liver disease. The death sparked an investigation and caution around gene therapy, which ultimately stalled the field for years.
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
Paul Gelsinger, Jesse Gelsinger’s father, speaks in 2007 at a senate public health subcommittee hearing about the health concerns associated with gene therapy.
(Image credit: Douglas Graham via Getty Images)
Quick facts
Milestone: First reported death due to gene therapy
Date: Sept. 17, 1999
Where: University of Pennsylvania, in Philadelphia
Who: Jesse Gelsinger
Twenty-six years ago today, on Sept. 17, a teenager who had received an experimental gene therapy died. His death led to needed changes in the clinical trial process while also spurring skepticism that would ultimately stall the field of gene therapy for years.
Jesse Gelsinger was an 18-year-old with ornithine transcarbamylase (OTC) deficiency, a genetic disease that affects about 1 in 40,000 newborns. The condition makes the body unable to make an enzyme that would normally break down ammonia, a natural waste product of metabolism. Without this enzyme, ammonia builds up in the body and poisons the blood.
About 90% of babies with the most severe form of OTC deficiency die. But Gelsinger — who had a milder, “late-onset” form of the disease — had reached adulthood by strictly adhering to a low-protein diet and a regimen of 50 pills a day, to help reduce the amount of ammonia in his blood and offset its effects. Although Gelsinger was small for his age and experienced a dangerous ammonia crisis when he stopped taking his pills, he was otherwise healthy.
You may like
8-year-old with rare, fatal disease shows dramatic improvement on experimental treatment
Experimental treatment for high cholesterol edits DNA in the body to reduce LDL
8 babies spared from potentially deadly inherited diseases through new IVF ‘mitochondrial donation’ trial
Gelsinger wanted to help newborns with the disease, so he enrolled in a trial to test the safety of a gene therapy aimed at correcting the defective OTC gene. The treatment used a weakened form of an adenovirus, a type of cold virus, to deliver the corrected form of the OTC gene into Gelsinger’s cells.
Gelsinger flew to the University of Pennsylvania, where the trial was being run, and had the treatment infused into the artery feeding the liver on Sept. 13, 1999. He had flu-like symptoms that day, as was expected. But by the next day, he was jaundiced, he developed a severe inflammatory reaction and a blood clotting disorder, and his organs began to fail. He was taken off life support around 2:30 p.m. on Sept. 17. Investigations revealed that his death was caused by a severe immune reaction to the virus used to deliver the treatment.
A Food and Drug Administration (FDA) investigation found numerous problems with Gelsinger’s enrollment in the trial, according to The New York Times. First, his liver function was too poor and ammonia levels were too high when he started the trial. Second, the team did not disclose to patients that, prior to the trial, lab animals had died from higher doses of the therapy. Additionally, other human participants had experienced serious side effects. Meanwhile, Dr. James Wilson, the lead investigator, owned stock in Genovo, the company developing the therapy, and stood to gain millions if the therapy was successful.
James Wilson was the lead investigator for the OTC gene therapy trial. That trial, along with other gene therapy trials at the University of Pennsylvania, were halted after Gelsinger’s death. Wilson continued to work in the field and has since been involved in the development of several gene therapy products, including ones for spinal muscular atrophy and an inherited form of blindness. (Image credit: Anadolu via Getty Images)
“We don’t know what the impact of these deviations are,” Dr. Kathryn Zoon, then-director of the FDA’s Center for Biologics Evaluation and Research, said at the time, The New York Times reported. “But they’re important.”
Sign up for the Live Science daily newsletter now
Get the world’s most fascinating discoveries delivered straight to your inbox.
Contact me with news and offers from other Future brandsReceive email from us on behalf of our trusted partners or sponsorsBy submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.
Gelsinger’s father, Paul Gelsinger, launched a wrongful-death suit against parties involved in the trial; it was eventually settled for an undisclosed sum.
Gelsinger’s death led to several changes in how gene therapy clinical trials are run and to stronger informed-consent requirements. All of the gene therapy trials underway at the University of Pennsylvania were halted. The FDA also started requiring greater monitoring for gene therapy trials.
The death cast a pall over the field, and as public and private funding for the approach dried up, gene therapy stalled. Eventually, however, with progress in understanding the viral vectors used to deliver gene therapy, and later, with the advent of the cut-and-paste gene editing tool CRISPR, the field has rebounded.
Scientists have now used gene therapy to treat many rare genetic disorders, including severe combined immune deficiency and multiple forms of blindness. The first CRISPR-based gene therapy, which treats sickle cell anemia by disabling a specific gene, was approved in January 2024. And in 2025, scientists announced that they’d used a customized CRISPR treatment designed for his particular gene mutation to treat a baby with a rare and devastating genetic syndrome.
RELATED STORIES
—Gene that human ancestors lost millions of years ago could help treat gout
—US baby receives first-ever customized CRISPR treatment for genetic disease
—In a first, congenital deafness in teens and adults treated with new gene therapy
Right now, the number of approved gene therapy products is still small. Many of those approved therapies use cells that are edited in the lab and then returned to the body to fight or treat cancer, rather than changing the genes in the nucleus of a patient’s own cells.
But the field has come a long way since Gelsinger’s death, and in 2021, scientists used gene therapy to successfully treat OTC deficiency.
Social Links Navigation
Managing Editor
Tia is the managing editor and was previously a senior writer for Live Science. Her work has appeared in Scientific American, Wired.com and other outlets. She holds a master’s degree in bioengineering from the University of Washington, a graduate certificate in science writing from UC Santa Cruz and a bachelor’s degree in mechanical engineering from the University of Texas at Austin. Tia was part of a team at the Milwaukee Journal Sentinel that published the Empty Cradles series on preterm births, which won multiple awards, including the 2012 Casey Medal for Meritorious Journalism.
You must confirm your public display name before commenting
Please logout and then login again, you will then be prompted to enter your display name.
8-year-old with rare, fatal disease shows dramatic improvement on experimental treatment
Experimental treatment for high cholesterol edits DNA in the body to reduce LDL
8 babies spared from potentially deadly inherited diseases through new IVF ‘mitochondrial donation’ trial
Breakthrough cystic fibrosis drug that extends life by decades earns its developers a $250,000 ‘American Nobel’
Scraps of ancient viruses make up 40% of our genome. They could trigger brain degeneration.
Diabetic man produces his own insulin after gene-edited cell transplant
Latest in Genetics
Gene that human ancestors lost millions of years ago could help treat gout
Scraps of ancient viruses make up 40% of our genome. They could trigger brain degeneration.
Scientists uncover ‘coils’ in DNA that form under pressure
Special protection may help human eggs stay fresh as the body ages
8 ‘hotspots’ in the genome linked to ME/CFS in largest study of its kind
Humans may have untapped ‘superpowers’ from genes related to hibernation, scientists claim
Latest in Features
Science history: A tragic gene therapy death that stalled the field for a decade — Sept. 17, 1999
Science history: Gravitational waves detected, proving Einstein right — Sept. 14, 2015
Volcanic ‘googly eyes’ stare into space from skull-like peninsula
James Webb telescope’s ‘starlit mountaintop’ could be the observatory’s best image yet — Space photo of the week
Where is Queen Boudica buried?
Camera trap in Chile detects strange lights blazing through the wilderness. Researchers are scrambling to explain them.
LATEST ARTICLES
‘We certainly weren’t exceptional, but now we’re the only ones left’: In new PBS series ‘Human,’ anthropologist Ella Al-Shamahi explores how humans came to dominate Earth
1,900-year-old ‘treasure’ found in Roman-era family’s scorched house in Romania
Skyscraper-size asteroid previously predicted to hit us in 60 years will zoom past Earth on Thursday (Sept. 18) — and you can see it live
Grumpy-looking Pallas’s cat photographed by camera trap in stunning photo from eastern Himalayas
Viltrox AF 16mm f/1.8 FE lens review
Live Science is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.
Contact Future’s experts
Terms and conditions
Privacy policy
Cookies policy
Accessibility Statement
Advertise with us
Web notifications
Editorial standards
How to pitch a story to us
Future US, Inc. Full 7th Floor, 130 West 42nd Street,
Please login or signup to comment
Please wait…
